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Objectives 




management in patients 
with an indication for 
both APT and OAC 
therapies 
1
Review reported DAT / 
TAT-related ADRs at 
BHM during the year 
2019
2
Discuss the clinical 
impact of pharmacist 
interventions in 
optimizing antithrombotic 
therapy in patients at 
BHM
3
Laura Provost, Baptist Hospital of Miami
Background
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Background
• Patients requiring concomitant APT and AC therapy have ↑ risk of 
both thrombotic and bleeding events
• Major bleeding is associated with 5x ↑ risk of death after ACS 
– Addition of single APT to OAC ↑ bleed risk up to 60%
– Addition of dual APT to OAC further ↑ this risk 2-3 fold 
• Goal: Mitigate bleed risk while maintaining 
antithrombotic efficacy
Kumbhani DJ, et al. J Am Coll Cardiol. 2021;77(5):629-658. Laura Provost, Baptist Hospital of Miami
Summary of Literature 
Most recent recommendations state that TAT be used for shortest duration possible (most often 
limited to duration of hospitalization)
2013-2018
Primary Literature
[WOEST, PIONEER-AF PCI, RE-DUAL PCI, 








• Management of combination antithrombotic therapy is driven by:
– Patient parameters, medication factors, guideline recommendations, indication, etc.
• Evolution of Triple Antithrombotic Therapy (TAT)
Laura Provost, Baptist Hospital of Miami
Antithrombotic-related ADRs at BHM











including multiple agents n=84
DAT or TAT Regimens 
• APT + IV AC 
• APT + OAC 
• 2 APT + OAC 







AC + AC (Bridge therapy) 6
• Antithrombotics were #1 medication class associated with ADRs in 2019 (~29%)
• 28% of these ADRs included DAT or TAT regimens (>1 APT + IV/PO AC) 
DAT=Dual Antithrombotic Therapy; TAT=Triple Antithrombotic Therapy
>75% of ADRs were community-acquired
Laura Provost, Baptist Hospital of Miami
Research Purpose 
To evaluate pharmacists’ role in the 
optimization of antithrombotic therapy in 
patients with concomitant indications for 
APT and OAC agents 
Laura Provost, Baptist Hospital of Miami
Methods
Laura Provost, Baptist Hospital of Miami
Study Design
Single center Quality 
Improvement
Prospective January – March 
31st 2021 
Laura Provost, Baptist Hospital of Miami
Eligibility Criteria 
Hospitalized adult patients at Baptist Hospital 














Dual Antithrombotic Therapy 
(DAT): 1 APT + OAC
Triple Antithrombotic Therapy 
(TAT): 2 APT + OAC
Laura Provost, Baptist Hospital of Miami
Data Collection
Daily report of 
hospitalized patients 
with active order for 
>1 antithrombotic 
agent
Filtered to include 
only patients 
receiving DAT or TAT
Recommendations 
made based on 
clinical guidelines, 
indications & patient 
characteristics
Laura Provost, Baptist Hospital of Miami
Study Outcomes 
• Appropriateness of AC and APT 
regimens based on specific 
indications 
Primary
• Type of pharmacist intervention
• Intervention acceptance rate
Secondary 
Laura Provost, Baptist Hospital of Miami
Results
Laura Provost, Baptist Hospital of Miami
Baseline Demographics 
n= 239
Mean age, years (SD) 74.3 + 12.1
Gender – male, n (%) 136 (56.9)










• S/p Valve surgery
• PAD
• Not documented









OAC Indication – n (%)
• Atrial Fibrillation 
• DVT/PE treatment 
























*Intracardiac thrombus, valve surgery, PAD, 
portal vein thrombosis, s/p hip/knee replacement
























Laura Provost, Baptist Hospital of Miami
Secondary Outcomes































Alternative Agent Recommended 4 4
Total 47 39 (83.0%)
Pharmacist Interventions
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Secondary Outcomes































Alternative Agent Recommended 4 4
Total 47 39 (83.0%)
Pharmacist Interventions
Laura Provost, Baptist Hospital of Miami
Secondary Outcomes































Alternative Agent Recommended 4 4
Total 47 39 (83.0%)
Pharmacist Interventions
Laura Provost, Baptist Hospital of Miami
Secondary Outcomes































Alternative Agent Recommended 4 4
Total 47 39 (83.0%)
Pharmacist Interventions
Laura Provost, Baptist Hospital of Miami
Secondary Outcomes































Alternative Agent Recommended 4 4
Total 47 39 (83.0%)
Pharmacist Interventions
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Dual Antithrombotic Regimens
Interventions Rec’d / Accepted
Increase OAC 12 / 9






Alternative Agent Rec’d 3 / 3




Accepted Rejected *35 unique regimens with 36 interventions
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Triple Antithrombotic Therapy
Interventions Rec’d / Accepted
Discontinue APT 7 / 7
Increase OAC 2 / 2
Decrease OAC 1 / 1
Alternative Agent Rec’d 1 / 1





*8 unique regimens with 11 interventions
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Discussion 
• Dual antithrombotic therapy (APT + OAC) accounted for 
95% of all regimens reviewed
• Triple antithrombotic therapies had the greatest opportunity 
for optimization 
– 73% inappropriate pre-intervention, 100% of interventions accepted
• Type of pharmacist intervention 
– Most common: APT discontinuation
– Most clinically significant: OAC discontinuation 
Laura Provost, Baptist Hospital of Miami
Limitations
Short study duration (10 weeks) 
Warfarin pharmacy consult and pre-approved automatic dose 
adjustment protocol in place to facilitate OAC dose optimization 
Patients assessed for therapy optimization only once
Unable to assess long-term impact of RPh intervention on adverse 
outcomes 
Laura Provost, Baptist Hospital of Miami
Conclusion
Pharmacist intervention resulted in optimization of dual / triple 
antithrombotic therapies by 15%, with greatest impact seen with 
triple antithrombotic therapy
• Next steps: 
– Implement an automated alert that requires providers to 
acknowledge the use of triple therapy as well as intended 
duration
– Pharmacist re-education regarding indication-specific dosing 
of OACs and indicated duration of therapy
Laura Provost, Baptist Hospital of Miami
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Self Assessment Question
When indicated, what is the most appropriate 
duration of triple antithrombotic therapy for 
most patients? 
A. Until hospital discharge 
B. Indefinitely 
C. 1 year 
D. Triple therapy is never appropriate 
Laura Provost, Baptist Hospital of Miami
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